文献速递甲状腺核医学核素与放射性配体治疗

核医学在良性甲状腺疾病临床管理中的作用(第1部分:甲状腺功能亢进症)

The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism.
PubMed 文献 · J Nucl Med · 2020-10-02

本文综述核医学在甲状腺功能亢进症(甲亢)诊疗中的作用。甲亢常见病因为Graves病、毒性多结节性甲状腺肿和毒性甲状腺腺瘤,超声联合实验室检查是一线诊断方法,放射性核素显像可鉴别病因并指导放射性碘治疗,131I治疗通常在抗甲状腺药物失败或手术禁忌时考虑。

要点

  • 超声联合实验室检查是鉴别甲亢病因的一线诊断方法。
  • 放射性核素显像可区分Graves病、毒性多结节性甲状腺肿、毒性甲状腺腺瘤及破坏性甲状腺炎。
  • 131I治疗通常在抗甲状腺药物失败、手术禁忌或患者拒绝手术时考虑。

核心结论

  • 甲状腺功能亢进症最常见的病因是自身免疫性甲亢(Graves病)、毒性多结节性甲状腺肿和毒性甲状腺腺瘤。
  • 放射性核素显像有助于鉴别甲亢的不同病因,并为放射性碘治疗提供规划信息。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • Graves病由针对促甲状腺激素(TSH)受体的自身抗体引起,毒性多结节性甲状腺肿和毒性甲状腺腺瘤由体细胞激活型功能获得性突变引起。
  • 甲亢典型实验室检查表现为TSH降低、游离甲状腺素和游离三碘甲状腺原氨酸升高,Graves病患者可见TSH受体自身抗体。
  • 超声用于确定甲状腺大小、血供及结节的位置、大小、数量和特征,与实验室检查结合构成鉴别不同甲亢类型的一线诊断方法。
  • 99mTc-甲氧基异丁基异腈显像可鉴别1型与2型胺碘酮诱导的甲亢。

关键数值与推荐

  • Graves病、毒性多结节性甲状腺肿、毒性甲状腺腺瘤和破坏性甲状腺炎各有特定的显像模式。
  • 甲状腺摄碘率测定为甲亢放射性碘治疗规划提供信息。
  • 毒性甲状腺腺瘤或毒性多结节性甲状腺肿患者放射性碘治疗的目标是达到甲状腺功能正常状态。
  • Graves病放射性碘治疗的目标是诱导甲状腺功能减退,该状态可通过口服甲状腺激素替代治疗管理。
  • 基于拟治疗甲状腺体积和摄碘率的剂量学估算应指导131I活度的选择。

临床怎么用

  • 甲亢可选用口服抗甲状腺药物、手术甲状腺切除术或131I治疗。
  • 放射性碘治疗一般在抗甲状腺药物治疗失败、手术禁忌或患者拒绝手术时考虑。
  • 放射性碘治疗早期副作用(典型为甲状腺轻度疼痛)可用非甾体抗炎药处理。

局限性

  • 放射性碘治疗后的迟发副作用为甲状腺功能减退和极小的辐射诱发恶性肿瘤风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Benign thyroid disorders, especially hyper- and hypothyroidism, are the most prevalent endocrine disorders. The most common etiologies of hyperthyroidism are autoimmune hyperthyroidism (Graves disease, GD), toxic multinodular goiter (TMNG), and toxic thyroid adenoma (TA). Less common etiologies include destructive thyroiditis (e.g., amiodarone-induced thyroid dysfunction) and factitious hyperthyroidism. GD is caused by autoantibodies against the thyroid-stimulating hormone (TSH) receptor. TMNG and TA are caused by a somatic activating gain-of-function mutation. Typical laboratory findings in patients with hyperthyroidism are low TSH, elevated free-thyroxine and free-triiodothyronine levels, and TSH-receptor autoantibodies in patients with GD. Ultrasound imaging is used to determine the size and vascularity of the thyroid gland and the location, size, number, and characteristics of thyroid nodules. Combined with lab tests, these features constitute the first-line diagnostic approach to distinguishing different forms of hyperthyroidism. Thyroid scintigraphy with either radioiodine or 99mTc-pertechnetate is useful to characterize different forms of hyperthyroidism and provides information for planning radioiodine therapy. There are specific scintigraphic patterns for GD, TMNG, TA, and destructive thyroiditis. Scintigraphy with 99mTc-sestamibi allows differentiation of type 1 from type 2 amiodarone-induced hyperthyroidism. The radioiodine uptake test provides information for planning radioiodine therapy of hyperthyroidism. Hyperthyroidism can be treated with oral antithyroid drugs, surgical thyroidectomy, or 131I-iodide. Radioiodine therapy is generally considered after failure of treatment with antithyroid drugs, or when surgery is contraindicated or refused by the patient. In patients with TA or TMNG, the goal of radioiodine therapy is to achieve euthyroid status. In GD, the goal of radioiodine therapy is to induce hypothyroidism, a status that is readily treatable with oral thyroid hormone replacement therapy. Dosimetric estimates based on the thyroid volume to be treated and on radioiodine uptake should guide selection of the 131I-activity to be administered. Early side effects of radioiodine therapy (typically mild pain in the thyroid) can be handled by nonsteroidal antiinflammatory drugs. Delayed side effects after radioiodine therapy for hyperthyroidism are hypothyroidism and a minimal risk of radiation-induced malignancies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mariani G, Tonacchera M, Grosso M, et al. The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism. J Nucl Med. 2020. PMID: 33008929. doi:10.2967/jnumed.120.243170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。